Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Burgess DC, et al. Among authors: keech ac. Eur Heart J. 2010 Jan;31(1):92-9. doi: 10.1093/eurheartj/ehp377. Epub 2009 Sep 29. Eur Heart J. 2010. PMID: 19797259 Clinical Trial.
Baseline data in clinical trials.
Burgess DC, Gebski VJ, Keech AC. Burgess DC, et al. Among authors: keech ac. Med J Aust. 2003 Jul 21;179(2):105-7. doi: 10.5694/j.1326-5377.2003.tb05447.x. Med J Aust. 2003. PMID: 12864724 Review. No abstract available.
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators. Taskinen MR, et al. Among authors: keech ac. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):950-5. doi: 10.1161/ATVBAHA.108.178228. Epub 2009 Mar 26. Arterioscler Thromb Vasc Biol. 2009. PMID: 19325138 Clinical Trial.
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, Davis TM, Colman PG, Manning P, Fulcher G, Keech AC; FIELD Study Investigators. Scott R, et al. Among authors: keech ac. Cardiovasc Diabetol. 2011 Nov 21;10:102. doi: 10.1186/1475-2840-10-102. Cardiovasc Diabetol. 2011. PMID: 22104275 Free PMC article. Clinical Trial.
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; FIELD Study Investigators. Ting RD, et al. Among authors: keech ac. Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210576 Free PMC article. Clinical Trial.
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Tonkin A, Hunt D, Voysey M, Kesäniemi A, Hamer A, Waites J, Mahar L, Mann S, Glasziou P, Forder P, Simes J, Keech AC; FIELD Study Investigators. Tonkin A, et al. Among authors: keech ac. Am Heart J. 2012 Mar;163(3):508-14. doi: 10.1016/j.ahj.2011.12.004. Am Heart J. 2012. PMID: 22424024 Free article. Clinical Trial.
Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.
Best JD, Drury PL, Davis TM, Taskinen MR, Kesäniemi YA, Scott R, Pardy C, Voysey M, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators. Best JD, et al. Among authors: keech ac. Diabetes Care. 2012 May;35(5):1165-70. doi: 10.2337/dc11-1307. Epub 2012 Mar 19. Diabetes Care. 2012. PMID: 22432105 Free PMC article. Clinical Trial.
201 results